稳定缺氧诱导因子来管理慢性病中的贫血:从基本理论到临床研究
1First Department of Clinical Medicine, Shaanxi University of Chinese Medicine, Xianyang, China.
Kidney diseases (Basel, Switzerland)
|April 25, 2024
概括
慢性病 (CKD) 中的贫血可以用新型缺氧诱导因子酸酶抑制剂 (HIF-PHI) 治疗. 这些药物有效地提高了血红蛋白水平,为CKD患者提供了新的治疗选择.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 贫血是慢性病 (CKD) 的常见并发症,影响患者的预后和生活质量.
- 患病脏减少红素蛋白 (EPO) 合成是主要原因,但炎症,缺铁和毒素也会导致.
- 慢性病中的贫血与心血管事件增加,死亡率和功能下降有关.
研究的目的:
- 审查低氧诱导因子酸酶抑制剂 (HIF-PHI) 在治疗贫血中的作用机制.
- 讨论HIF-PHI在慢性病患者的疗效,无论是在透析中还是脱离透析.
- 突出与HIF-PHI治疗相关的潜在安全考虑因素.
主要方法:
- 审查HIF路径结构和稳定机制.
- 对临床试验数据分析 HIF-PHI 在CKD贫血中的疗效.
- 讨论安全性概况和对红色素形成刺激剂 (ESAs) 的比较有效性.
主要成果:
- HIF-PHI激活缺氧诱导因子 (HIF) 途径,刺激EPO的产生和改善铁的利用.
- 临床试验表明,HIF-PHI在增加血红蛋白水平方面与ESA相当.
- HIF-PHI为CKD患者的贫血提供了一种新的治疗策略.
结论:
- HIF-PHI代表了一种有前途的新类药物,用于治疗慢性脏疾病中的贫血.
- 了解HIF-PHI的机制和安全性对于其临床应用至关重要.
- 进一步的研究可能会阐明HIF-PHI在CKD管理中的长期益处和最佳使用.
相关概念视频
Factors Affecting Erythropoiesis
3.3K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.3K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Role of Hematopoietic Growth Factors
1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
Hypoxia
1.0K
Hypoxia is a medical condition characterized by an inadequate oxygen supply to body tissues. It typically manifests as a bluish discoloration of the skin and mucosae, especially in fair-skinned individuals, when hemoglobin (Hb) saturation drops below 75%.
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
1.0K
Erythropoiesis
4.2K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.2K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
199
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
199


